The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genmab (Inst); Genzyme (Inst); Genzyme (Inst); Hedera Dx (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); PharmaMar (Inst); Roche/Genentech (Inst); Sanofi (Inst); socar (Inst); Taiho Pharmaceutical (Inst); Turning Point Therapeutics (Inst)
 
Gilberto Castro
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Libbs; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi; Takeda; Yuhan
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BerGenBio; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; F. Hoffmann LaRoche; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; F. Hoffmann LaRoche; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; Touch Oncology
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRIFOLS
 
Katerina A. Politi
Consulting or Advisory Role - AstraZeneca; Halda Therapeutics; Janssen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); D2G Oncology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent licensed by MSKCC to Molecular MD for T790M testing
Travel, Accommodations, Expenses - AstraZeneca; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Lung Cancer Research Foundation
 
Toshiaki Takahashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD K.K.; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yakult Honsha
Research Funding - Amgen (Inst); AstraZeneca Japan (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Merck (Inst); MSD K.K. (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Jie Wang
No Relationships to Disclose
 
Emma Dean
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca (I); AstraZeneca/MedImmune
Travel, Accommodations, Expenses - AstraZeneca
 
Melissa Deans
Employment - AstraZeneca
 
Helen Broadhurst
Employment - AstraZeneca
 
Piruntha Thiyagarajah
Employment - AstraZeneca
 
Patrick M. Forde
Consulting or Advisory Role - Amgen; Ascendis Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; CureVac; Daiichi Sankyo/UCB Japan; F-Star Biotechnology; Fosun Pharma; G1 Therapeutics; Genentech; Gilead Sciences; ITeos Therapeutics; Janssen; Merck; Novartis; Regeneron; Sanofi; Surface Oncology; Synthekine; Teva
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals; Kyowa Hakko Kirin (Inst); Novartis (Inst); Regeneron